AbCellera, a clinical-stage biotechnology company developing antibody-based medicines in endocrinology, women’s health, immunology, and oncology, has appointed Dr. Sarah Noonberg, MD, PhD, as Chief Medical Officer. Noonberg, a board-certified physician-scientist, brings over two decades of experience leading development programs from discovery to regulatory approvals and commercialization across diverse therapeutic areas, including oncology, neuroscience, rare diseases, gene therapy, and cell therapy. Her expertise will support AbCellera’s efforts to advance its clinical pipeline and expand its portfolio of antibody-based therapeutics.
Carl Hansen, PhD, Founder and CEO of AbCellera, said, “With more than 20 years of experience in clinical development, Sarah brings deep expertise and proven operational and leadership strength that will be invaluable as we continue to build and advance our clinical pipeline.”
Noonberg added, “I'm honored to join AbCellera at such an exciting time as it transitions to a clinical stage company. I look forward to working with the team to advance a growing portfolio of important therapies that have the potential to improve patients’ lives.” Noonberg previously served as Chief Medical Officer at Metagenomi, Maze Therapeutics, Nohla Therapeutics, and Prothena Biosciences, and has held senior roles at BioMarin and Medivation, contributing to the development of XTANDI for prostate cancer.